{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:22:16Z","timestamp":1784280136659,"version":"3.55.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000092","name":"Ontario Genomics Institute","doi-asserted-by":"publisher","award":["OGI-147"],"award-info":[{"award-number":["OGI-147"]}],"id":[{"id":"10.13039\/501100000092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","award":["OGI-147"],"award-info":[{"award-number":["OGI-147"]}],"id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ontario Research Fund"},{"DOI":"10.13039\/501100010787","name":"Genome Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000233","name":"Genome British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000233","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013062","name":"G\u00e9nome Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014429","name":"Children's Hospital of Eastern Ontario Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Genome Canada\/Genome Alberta GAPP Grant"},{"DOI":"10.13039\/501100010785","name":"Canada First Research Excellence Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010785","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canada Research Chair in Rare Disease Precision Health"},{"name":"Canada Research Chair in Genomics and Health Policy"},{"name":"Svare Chair for Value and Socioeconomic Impact in Child Health Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40258-024-00936-7","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T16:48:10Z","timestamp":1735577290000},"page":"453-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exome Sequencing in the Diagnostic Pathway for Suspected Rare Genetic Diseases: Does the Order of Testing Affect its Cost-Effectiveness?"],"prefix":"10.1007","volume":"23","author":[{"given":"Koen","family":"Degeling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Tagimacruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen V.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor A.","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Fooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viji","family":"Venkataramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kym M.","family":"Boycott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois P.","family":"Bernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mendoza-Londono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taila","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin Z.","family":"Hayeems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8467-8008","authenticated-orcid":false,"given":"Deborah A.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Care4Rare Canada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"936_CR1","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/ajmg.a.61124","volume":"179","author":"CR Ferreira","year":"2019","unstructured":"Ferreira CR. The burden of rare diseases. Am J Med Genet A. 2019;179:885\u201392.","journal-title":"Am J Med Genet A"},{"key":"936_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jval.2018.03.002","volume":"21","author":"S Auvin","year":"2018","unstructured":"Auvin S, Irwin J, Abi-Aad P, Battersby A. The problem of rarity: estimation of prevalence in rare disease. Value Health. 2018;21:501\u20137.","journal-title":"Value Health."},{"key":"936_CR3","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1056\/NEJMoa2035790","volume":"385","author":"D Smedley","year":"2021","unstructured":"The 100,000 Genomes Project Pilot Investigators, Smedley D, Smith KR, Martin A, Thomas EA, McDonagh EM, et al. 100,000 genomes pilot on rare-disease diagnosis in health care\u2014preliminary report. N Engl J Med. 2021;385:1868\u201380.","journal-title":"N Engl J Med"},{"key":"936_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/gim.2013.99","volume":"16","author":"V Shashi","year":"2014","unstructured":"Shashi V, McConkie-Rosell A, Rosell B, Schoch K, Vellore K, McDonald M, et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. Genet Med. 2014;16:176\u201382.","journal-title":"Genet Med"},{"key":"936_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1146\/annurev-genom-083118-015345","volume":"21","author":"T Hartley","year":"2020","unstructured":"Hartley T, Lemire G, Kernohan KD, Howley HE, Adams DR, Boycott KM. New diagnostic approaches for undiagnosed rare genetic diseases. Annu Rev Genom Hum Genet. 2020;21:351\u201372.","journal-title":"Annu Rev Genom Hum Genet"},{"key":"936_CR6","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/gim.2015.200","volume":"18","author":"GR Monroe","year":"2016","unstructured":"Monroe GR, Frederix GW, Savelberg SMC, de Vries TI, Duran KJ, van der Smagt JJ, et al. Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability. Genet Med. 2016;18:949\u201356.","journal-title":"Genet Med"},{"key":"936_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40273-019-00856-8","volume":"38","author":"P Fahr","year":"2020","unstructured":"Fahr P, Buchanan J, Wordsworth S. A review of health economic studies comparing traditional and massively parallel sequencing diagnostic pathways for suspected genetic disorders. Pharmacoeconomics. 2020;38:143\u201358.","journal-title":"Pharmacoeconomics"},{"key":"936_CR8","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/gim.2014.58","volume":"16","author":"A Iglesias","year":"2014","unstructured":"Iglesias A, Anyane-Yeboa K, Wynn J, Wilson A, Truitt Cho M, Guzman E, et al. The usefulness of whole-exome sequencing in routine clinical practice. Genet Med. 2014;16:922\u201331.","journal-title":"Genet Med"},{"key":"936_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ejpn.2014.12.014","volume":"19","author":"KJM van Nimwegen","year":"2015","unstructured":"van Nimwegen KJM, Schieving JH, Willemsen MAAP, Veltman JA, van der Burg S, van der Wilt GJ, et al. The diagnostic pathway in complex paediatric neurology: a cost analysis. Eur J Paediatr Neurol. 2015;19:233\u20139.","journal-title":"Eur J Paediatr Neurol"},{"key":"936_CR10","doi-asserted-by":"publisher","first-page":"F1000 Faculty R","DOI":"10.12688\/f1000research.19444.1","volume":"9","author":"JP Ross","year":"2020","unstructured":"Ross JP, Dion PA, Rouleau GA. Exome sequencing in genetic disease: recent advances and considerations. F1000Research. 2020;9:F1000 Faculty Rev-336.","journal-title":"F1000Research."},{"key":"936_CR11","doi-asserted-by":"crossref","unstructured":"Thompson R, Drew CJG, Thomas RH. Chapter two\u2014next generation sequencing in the clinical domain: clinical advantages, practical, and ethical challenges. In: Rees MI, editor. Adv Protein Chem Struct Biol [Internet]. Academic Press; 2012 [cited 2024 May 9]. p. 27\u201363. https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780123942876000021.","DOI":"10.1016\/B978-0-12-394287-6.00002-1"},{"key":"936_CR12","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3390\/cancers7040874","volume":"7","author":"R Luthra","year":"2015","unstructured":"Luthra R, Chen H, Roy-Chowdhuri S, Singh RR. Next-generation sequencing in clinical molecular diagnostics of cancer: advantages and challenges. Cancers. 2015;7:2023\u201336.","journal-title":"Cancers"},{"key":"936_CR13","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/gim.2017.1","volume":"19","author":"LELM Vissers","year":"2017","unstructured":"Vissers LELM, van Nimwegen KJM, Schieving JH, Kamsteeg E-J, Kleefstra T, Yntema HG, et al. A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology. Genet Med. 2017;19:1055\u201363.","journal-title":"Genet Med"},{"key":"936_CR14","unstructured":"Stavropoulos J, Shago M, Bruyere H, Chan M, Chernos J, Chun K, et al. CCMG guidelines for genomic microarray testing. Can Coll Med Genet [Internet]. 2016 [cited 2024 May 6]. https:\/\/www.academia.edu\/download\/45196784\/CCMG_Guidelines_for_Genomic_Microarray_T20160429-32558-p3l2wp.pdf."},{"key":"936_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/jmedgenet-2015-103144","volume":"52","author":"K Boycott","year":"2015","unstructured":"Boycott K, Hartley T, Adam S, Bernier F, Chong K, Fernandez BA, et al. The clinical application of genome-wide sequencing for monogenic diseases in Canada: position statement of the Canadian College of Medical Geneticists. J Med Genet. 2015;52:431\u20137.","journal-title":"J Med Genet"},{"key":"936_CR16","doi-asserted-by":"crossref","unstructured":"Kchouk M, Gibrat JF, Elloumi M. Generations of Sequencing Technologies: From First to Next Generation. Biol Med [Internet]. 2017 [cited 2024 May 9];09. https:\/\/www.omicsonline.com\/open-access\/generations-of-sequencing-technologies-from-first-to-next-generation-0974-8369-1000395.php?aid=87862.","DOI":"10.4172\/0974-8369.1000395"},{"key":"936_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41436-019-0635-6","volume":"22","author":"N Dragojlovic","year":"2020","unstructured":"Dragojlovic N, van Karnebeek CDM, Ghani A, Genereaux D, Kim E, Birch P, et al. The cost trajectory of the diagnostic care pathway for children with suspected genetic disorders. Genet Med. 2020;22:292\u2013300.","journal-title":"Genet Med"},{"key":"936_CR18","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/gim.2017.247","volume":"20","author":"K Schwarze","year":"2018","unstructured":"Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 2018;20:1122\u201330.","journal-title":"Genet Med"},{"key":"936_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/2191-1991-3-29","volume":"3","author":"M Frank","year":"2013","unstructured":"Frank M, Prenzler A, Eils R, Graf von der Schulenburg J-M. Genome sequencing: a systematic review of health economic evidence. Health Econ Rev. 2013;3:29.","journal-title":"Health Econ Rev."},{"key":"936_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/gim.2017.226","volume":"20","author":"N Dragojlovic","year":"2018","unstructured":"Dragojlovic N, Elliott AM, Adam S, van Karnebeek C, Lehman A, Mwenifumbo JC, et al. The cost and diagnostic yield of exome sequencing for children with suspected genetic disorders: a benchmarking study. Genet Med. 2018;20:1\u20139.","journal-title":"Genet Med"},{"key":"936_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/cge.14313","volume":"103","author":"A Rezapour","year":"2023","unstructured":"Rezapour A, Souresrafil A, Barzegar M, Sheikhy-Chaman M, Tatarpour P. Economic evaluation of next-generation sequencing techniques in diagnosis of genetic disorders: a systematic review. Clin Genet. 2023;103:513\u201328.","journal-title":"Clin Genet"},{"key":"936_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41576-023-00683-w","volume":"25","author":"KD Kernohan","year":"2024","unstructured":"Kernohan KD, Boycott KM. The expanding diagnostic toolbox for rare genetic diseases. Nat Rev Genet. 2024;25:401\u201315.","journal-title":"Nat Rev Genet"},{"key":"936_CR23","unstructured":"Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A Health Technology Assessment [Internet]. Ontario Health; 2020 [cited 2021 Oct 4]. https:\/\/www.hqontario.ca\/Portals\/0\/Documents\/evidence\/reports\/hta-genome-wide-sequencing.pdf."},{"key":"936_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41436-020-01012-w","volume":"23","author":"C Li","year":"2021","unstructured":"Li C, Vandersluis S, Holubowich C, Ungar WJ, Goh ES, Boycott KM, et al. Cost-effectiveness of genome-wide sequencing for unexplained developmental disabilities and multiple congenital anomalies. Genet Med. 2021;23:451\u201360.","journal-title":"Genet Med"},{"key":"936_CR25","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462321001732","volume":"38","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Int J Technol Assess Health Care. 2022;38: e13.","journal-title":"Int J Technol Assess Health Care"},{"key":"936_CR26","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.gim.2021.11.005","volume":"24","author":"RZ Hayeems","year":"2022","unstructured":"Hayeems RZ, Michaels-Igbokwe C, Venkataramanan V, Hartley T, Acker M, Gillespie M, et al. The complexity of diagnosing rare disease: an organising framework for outcomes research and health economics based on real-world evidence. Genet Med. 2022;24:694\u2013702.","journal-title":"Genet Med"},{"key":"936_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061468","volume":"12","author":"RZ Hayeems","year":"2022","unstructured":"Hayeems RZ, Bernier F, Boycott KM, Hartley T, Michaels-Igbokwe C, Marshall DA. Positioning whole exome sequencing in the diagnostic pathway for rare disease to optimise utility: a protocol for an observational cohort study and an economic evaluation. BMJ Open. 2022;12: e061468.","journal-title":"BMJ Open"},{"key":"936_CR28","unstructured":"R Core Team. _R: a Language and Environment for Statistical Computing_. R Foundation for Statistical Computing [Internet]. Vienna, Austria; 2023. https:\/\/www.R-project.org\/. Accessed 8 Dec 2023."},{"key":"936_CR29","doi-asserted-by":"crossref","unstructured":"Ucar I, Smeets B, Azcorra A. simmer: Discrete-event simulation for R. J Stat Softw [Internet]. 2019 [cited 2023 Dec 8];90. http:\/\/arxiv.org\/abs\/1705.09746","DOI":"10.18637\/jss.v090.i02"},{"key":"936_CR30","first-page":"800","volume":"43","author":"HG Driver","year":"2022","unstructured":"Driver HG, Hartley T, Price EM, Turinsky AL, Buske OJ, Osmond M, et al. Genomics4RD: An integrated platform to share Canadian deep-phenotype and multiomic data for international rare disease gene discovery. Hum Mutat. 2022;43:800\u201311.","journal-title":"Hum Mutat"},{"key":"936_CR31","unstructured":"Bank of Canada. Annual Average Exchange Rates [Internet]. [cited 2023 Jan 1]. https:\/\/www.bankofcanada.ca\/rates\/exchange\/annual-average-exchange-rates\/."},{"key":"936_CR32","unstructured":"Statistics Canada. Consumer Price Index [Internet]. [cited 2023 Jan 1]. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1810000501."},{"key":"936_CR33","doi-asserted-by":"crossref","unstructured":"Jackson CH. flexsurv: a platform for parametric survival modeling in R. J Stat Softw [Internet]. 2016 [cited 2023 Dec 8];70. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5868723\/.","DOI":"10.18637\/jss.v070.i08"},{"key":"936_CR34","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13023-021-01907-0","volume":"16","author":"F Gorini","year":"2021","unstructured":"Gorini F, Coi A, Mezzasalma L, Baldacci S, Pierini A, Santoro M. Survival of patients with rare diseases: a population-based study in Tuscany (Italy). Orphanet J Rare Dis. 2021;16:275.","journal-title":"Orphanet J Rare Dis"},{"key":"936_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"936_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0272989X18814770","volume":"39","author":"K Degeling","year":"2019","unstructured":"Degeling K, Koffijberg H, Franken MD, Koopman M, IJzerman MJ. Comparing strategies for modeling competing risks in discrete-event simulations: a simulation study and illustration in colorectal cancer. Med Decis Mak. 2019;39:57\u201373.","journal-title":"Med Decis Mak"},{"key":"936_CR37","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12874-017-0437-y","volume":"17","author":"K Degeling","year":"2017","unstructured":"Degeling K, IJzerman MJ, Koopman M, Koffijberg H. Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models. BMC Med Res Methodol. 2017;17:170.","journal-title":"BMC Med Res Methodol"},{"key":"936_CR38","unstructured":"Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: CADTH, Ottowa, Canada (4th Edition). 2017."},{"key":"936_CR39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989X12458348","volume":"32","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Mak. 2012;32:722\u201332.","journal-title":"Med Decis Mak"},{"key":"936_CR40","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s40273-020-00914-6","volume":"38","author":"M Paulden","year":"2020","unstructured":"Paulden M. Calculating and Interpreting ICERs and net benefit. Pharmacoeconomics. 2020;38:785\u2013807.","journal-title":"Pharmacoeconomics"},{"key":"936_CR41","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015."},{"key":"936_CR42","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1080\/02664763.2010.545119","volume":"38","author":"G Barbato","year":"2011","unstructured":"Barbato G, Barini EM, Genta G, Levi R. Features and performance of some outlier detection methods. J Appl Stat. 2011;38:2133\u201349.","journal-title":"J Appl Stat"},{"key":"936_CR43","unstructured":"Thacker BH, Doebling SW, Hemez FM, Anderson MC, Pepin JE, Rodriguez EA. Concepts of model verification and validation. Los Alamos National Lab., Los Alamos, United States; 2004. p. 41."},{"key":"936_CR44","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jamapediatrics.2017.1755","volume":"171","author":"TY Tan","year":"2017","unstructured":"Tan TY, Dillon OJ, Stark Z, Schofield D, Alam K, Shrestha R, et al. Diagnostic impact and cost-effectiveness of whole-exome sequencing for ambulant children with suspected monogenic conditions. JAMA Pediatr. 2017;171:855\u201362.","journal-title":"JAMA Pediatr"},{"key":"936_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41525-018-0053-8","volume":"3","author":"MM Clark","year":"2018","unstructured":"Clark MM, Stark Z, Farnaes L, Tan TY, White SM, Dimmock D, et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. Npj Genom Med. 2018;3:1\u201310.","journal-title":"Npj Genom Med"},{"key":"936_CR46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41436-018-0006-8","volume":"21","author":"Z Stark","year":"2019","unstructured":"Stark Z, Schofield D, Martyn M, Rynehart L, Shrestha R, Alam K, et al. Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness. Genet Med. 2019;21:173\u201380.","journal-title":"Genet Med"},{"key":"936_CR47","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/gim.2016.221","volume":"19","author":"Z Stark","year":"2017","unstructured":"Stark Z, Schofield D, Alam K, Wilson W, Mupfeki N, Macciocca I, et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. Genet Med. 2017;19:867\u201374.","journal-title":"Genet Med"},{"key":"936_CR48","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.ajhg.2010.04.006","volume":"86","author":"DT Miller","year":"2010","unstructured":"Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86:749\u201364.","journal-title":"Am J Hum Genet"},{"key":"936_CR49","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1097\/GIM.0b013e3182217a3a","volume":"13","author":"HM Kearney","year":"2011","unstructured":"Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South ST. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. Genet Med. 2011;13:680\u20135.","journal-title":"Genet Med"},{"key":"936_CR50","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/GIM.0b013e3181f8baad","volume":"12","author":"M Manning","year":"2010","unstructured":"Manning M, Hudgins L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet Med. 2010;12:742\u20135.","journal-title":"Genet Med"},{"key":"936_CR51","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1038\/s41436-019-0583-1","volume":"21","author":"DA Marshall","year":"2019","unstructured":"Marshall DA, MacDonald KV, Heidenreich S, Hartley T, Bernier FP, Gillespie MK, et al. The value of diagnostic testing for parents of children with rare genetic diseases. Genet Med. 2019;21:2798\u2013806.","journal-title":"Genet Med"},{"key":"936_CR52","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s12687-021-00541-4","volume":"13","author":"M Abbott","year":"2022","unstructured":"Abbott M, McKenzie L, Moran BVG, Heidenreich S, Hern\u00e1ndez R, Hocking-Mennie L, et al. Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland. J Community Genet. 2022;13:487\u2013501.","journal-title":"J Community Genet"},{"key":"936_CR53","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/epi.14087","volume":"59","author":"KB Howell","year":"2018","unstructured":"Howell KB, Eggers S, Dalziel K, Riseley J, Mandelstam S, Myers CT, et al. A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy. Epilepsia. 2018;59:1177\u201387.","journal-title":"Epilepsia"},{"key":"936_CR54","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/gim.2017.47","volume":"19","author":"K Tsiplova","year":"2017","unstructured":"Tsiplova K, Zur RM, Marshall CR, Stavropoulos DJ, Pereira SL, Merico D, et al. A microcosting and cost\u2013consequence analysis of clinical genomic testing strategies in autism spectrum disorder. Genet Med. 2017;19:1268\u201375.","journal-title":"Genet Med"},{"key":"936_CR55","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.53514","volume":"7","author":"MC Nurchis","year":"2024","unstructured":"Nurchis MC, Radio FC, Salmasi L, Heidar Alizadeh A, Raspolini GM, Altamura G, et al. Cost-effectiveness of whole-genome vs whole-exome sequencing among children with suspected genetic disorders. JAMA Netw Open. 2024;7: e2353514.","journal-title":"JAMA Netw Open"},{"key":"936_CR56","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/children8050381","volume":"8","author":"H-F Chen","year":"2021","unstructured":"Chen H-F, Rose AM, Waisbren S, Ahmad A, Prosser LA. Newborn screening and treatment of phenylketonuria: projected health outcomes and cost-effectiveness. Children. 2021;8:381.","journal-title":"Children"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00936-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-024-00936-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00936-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T14:03:54Z","timestamp":1746453834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-024-00936-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["936"],"URL":"https:\/\/doi.org\/10.1007\/s40258-024-00936-7","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"1 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Genome Canada and the Ontario Genomics Institute (OGI-147), the Canadian Institutes of Health Research, Ontario Research Fund, Genome Alberta, Genome British Columbia, Genome Quebec, the Children\u2019s Hospital of Eastern Ontario Foundation, a Genome Canada\/Genome Alberta GAPP Grant, and the One Child Every Child initiative. The One Child Every Child initiative is supported by a grant from the Canada First Research Excellence Fund. Kym M Boycott is supported by a Canada Research Chair in Rare Disease Precision Health (Tier 1). Robin Z Hayeems is supported by the Canada Research Chair in Genomics and Health Policy (Tier 2). Deborah A Marshall is supported by the Svare Chair for Value and Socioeconomic Impact in Child Health Research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding\/support"}},{"value":"At the time of publication, KD was an employee of GlaxoSmithKline (GSK), but GSK was not involved in this research in any way, nor did this author contribute to this research in the capacity of his role within GSK. DAM, FPB, KMB, KF, KVM, RH, RML, TH, TAS, TT, and VV do not have any conflict of interest related to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data supporting this study have been collected using the Care Pathway data collection surveys in Genomics4RD, the official database for Care4Rare Canada, and are available upon controlled-access request and approval.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code is available upon controlled-access request and approval from the first and the corresponding authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The research protocol for CareRare SOLVE was approved by Clinical Trials Ontario (CTO-1577), the provincial platform responsible for approving clinical trials and observational studies involving two or more academic or healthcare institutions in Ontario, and by research ethics boards at the University of Calgary (REB18-0744 and REB20-1449) and University of Alberta (Pro00091561). Informed consent was obtained from all individual participants (legal guardians for participants aged <18 years) enrolled in the Care4Rare-SOLVE study. The informed consent form included information about the publication of results from the study, which will be published in aggregate.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Concept and design (DAM, FPB, KD, KMB, KVM, RH, RML, TAS, TH, TT), Acquisition of data (DAM, FPB, KMB, KF, RH, RML, TH, VV), Analysis (DAM, KD, TAS, TT) and interpretation of data (DAM, KD, KVM, RH, TAS, TT), Drafting of the manuscript (DAM, KD, TT), Critical revision of the paper for important intellectual content (DAM, FPB, KD, KMB, KVM, RH, RML, TAS, TH, TT), Obtaining funding (DAM, FPB, KMB, RH), Administrative, Technical, or Logistic support (DAM, KF, RH, TAS, VV), Supervision (DAM, KMB); All authors have read and approved the final version to be published.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}